How Arjuna Works
The bark is the medicinal part, traditionally prepared as a powder (churna) or decoction, and available today as standardized extract in supplement form. Its cardiovascular activity comes from several compound classes working together.
Tannins (arjunic acid, arjunolic acid, arjungenin) are powerful antioxidants that protect heart muscle cells from oxidative damage during periods of reduced blood flow. They also inhibit ACE (angiotensin-converting enzyme), which relaxes blood vessels and lowers blood pressure. [4]
Triterpenoid glycosides (arjunoside I–IV) appear to directly strengthen cardiac contractions — a property called positive inotropy — without increasing oxygen demand the way stimulant drugs do. This makes them potentially useful in heart failure and impaired cardiac output. [4]
Flavonoids (arjunone, isovitexin, vitexin) contribute anti-inflammatory and anti-atherosclerotic effects, reducing LDL cholesterol oxidation and slowing the buildup of arterial plaques. [5]
Practical use
The traditional dose is 500 mg of bark powder two to three times daily, often taken with warm milk or water. Standardized extracts providing around 10–15% tannins are also widely available and offer more consistent potency. Arjuna is typically taken over weeks to months — cumulative benefit is where it excels rather than acute effects.
Cholesterol and lipids
Several trials found that T. arjuna reduces total cholesterol, LDL, and triglycerides while modestly raising HDL. [2] It works best as an adjunct to diet and lifestyle changes.
Angina and exercise tolerance
By improving microcirculation, reducing arterial stiffness, and protecting cardiac tissue from oxidative stress, arjuna has shown particular promise for reducing angina frequency. In a crossover trial, 500 mg three times daily reduced angina episodes to a degree comparable to low-dose isosorbide mononitrate. [1]
See our Hawthorn Berry page for another well-studied herbal option for cardiovascular support.
Evidence Review
Antianginal effects — Dwivedi & Agarwal (1994)
This double-blind crossover trial (PMID 7741874) compared Terminalia arjuna 500 mg three times daily against isosorbide mononitrate in patients with stable angina pectoris over three months. T. arjuna significantly reduced angina episode frequency and improved treadmill exercise tolerance. The magnitude of benefit was comparable to the reference drug, and the herb was well tolerated without notable adverse effects. This was the foundational trial establishing arjuna as a viable adjunct in angina management. [1]
Coronary artery disease outcomes — Dwivedi & Jauhari (1997)
A three-month study (PMID 9505018) in patients with coronary artery disease found that T. arjuna bark powder 500 mg three times daily produced meaningful reductions in total cholesterol (9.7%), LDL cholesterol (15.8%), and triglycerides (12.7%), with a modest increase in HDL. Patients also reported reduced angina frequency and improved quality-of-life scores. Left ventricular mass — a marker of cardiac hypertrophy and risk — decreased significantly with treatment. [2]
Ischemic mitral regurgitation — Dwivedi et al. (2005)
This trial (PMID 15837100) examined T. arjuna in 40 post-myocardial infarction patients with ischemic mitral regurgitation (IMR), a condition where the mitral valve fails to close properly due to heart muscle damage. Patients receiving adjuvant T. arjuna over three months showed significant reduction in regurgitation severity on echocardiography, along with a roughly 50% reduction in angina frequency. The placebo group showed no improvement. The mechanism was attributed to improved ventricular geometry and reduced ischemia. [3]
Anti-inflammatory mechanisms — Kapoor et al. (2015)
This combined in vitro and in vivo study (PMID 25827448) in stable coronary artery disease patients demonstrated that 12 weeks of T. arjuna supplementation reduced circulating inflammatory markers including CRP and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). The herb also attenuated the Th1/Th2 cytokine imbalance characteristic of chronic cardiovascular inflammation. These findings provide mechanistic support for the clinical observations — arjuna appears to dampen the inflammatory processes that drive atherosclerosis progression. [6]
Comprehensive reviews — Maulik & Talwar (2012) and Dwivedi & Chopra (2014)
Two review papers (PMIDs 22583146 and 25379463) synthesize the experimental and clinical literature. They confirm that T. arjuna's cardiovascular activity includes: antioxidant protection of cardiac mitochondria, mild blood pressure reduction via ACE inhibition, anti-atherosclerotic effects via LDL oxidation inhibition, and direct inotropic effects on cardiac muscle without increasing myocardial oxygen demand. Both reviews note that while the evidence base is promising, most trials are small and short-term, and the herb works best as adjunct therapy rather than a replacement for established medications. [4][5]
Safety and considerations
Terminalia arjuna has a long history of traditional use and appears well tolerated at clinical doses. Reported side effects are generally mild and include occasional nausea, constipation, or headache. Because of its blood pressure-lowering and lipid-modifying effects, people already on antihypertensives or statins should use it under medical supervision. Safety data during pregnancy or breastfeeding have not been established.